Figure 4.
Figure 4. CD83 expression on DCs treated with endothelin receptor antagonists. Results of flow cytometry analysis of DCs stained with CD83 antibodies. Representative histograms are shown from 5 independent experiments. DCs indicates immature DCs; DC + SA, mature DCs; DC + SA + ABT-627, mature DCs treated with ETA receptor antagonist ABT-627 for 48 hours, leading to a significant lowering of CD83 expression in comparison with mature DCs (P < .001); and DC + SA + A-192621, mature DCs treated with ETB receptor antagonist A-192621 for 48 hours, displaying a significant increase in CD83 expression in comparison with mature DCs (P = .014). Isotype control (black line) was anti-immunoglobulin G-conjugated to phycoerythrin. Cells stained with CD83 are indicated by gray lines. Numbers on the horizontal bar indicate the percentage of cells positive for CD83.

CD83 expression on DCs treated with endothelin receptor antagonists. Results of flow cytometry analysis of DCs stained with CD83 antibodies. Representative histograms are shown from 5 independent experiments. DCs indicates immature DCs; DC + SA, mature DCs; DC + SA + ABT-627, mature DCs treated with ETA receptor antagonist ABT-627 for 48 hours, leading to a significant lowering of CD83 expression in comparison with mature DCs (P < .001); and DC + SA + A-192621, mature DCs treated with ETB receptor antagonist A-192621 for 48 hours, displaying a significant increase in CD83 expression in comparison with mature DCs (P = .014). Isotype control (black line) was anti-immunoglobulin G-conjugated to phycoerythrin. Cells stained with CD83 are indicated by gray lines. Numbers on the horizontal bar indicate the percentage of cells positive for CD83.

Close Modal

or Create an Account

Close Modal
Close Modal